Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ZURA 
Zura Bio Limited Class A Ordinary Shares (ZURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZURA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.33
1 Year Target Price $13.33
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.96% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 223.01M USD | Price to earnings Ratio - | 1Y Target Price 13.33 |
Price to earnings Ratio - | 1Y Target Price 13.33 | ||
Volume (30-day avg) 7 | Beta 0.25 | 52 Weeks Range 0.97 - 4.98 | Updated Date 10/17/2025 |
52 Weeks Range 0.97 - 4.98 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.74 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.05% | Return on Equity (TTM) -43.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 112084037 | Price to Sales(TTM) - |
Enterprise Value 112084037 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 65018058 | Shares Floating 37881471 |
Shares Outstanding 65018058 | Shares Floating 37881471 | ||
Percent Insiders 27.75 | Percent Institutions 51.22 |
Upturn AI SWOT
Zura Bio Limited Class A Ordinary Shares
Company Overview
History and Background
Zura Bio Limited is a clinical-stage immunology company focused on developing novel medicines for immune and inflammatory diseases. The company was founded with the aim of addressing unmet needs in autoimmune and inflammatory conditions.
Core Business Areas
- Drug Development: Focuses on research and development of therapeutic candidates for autoimmune and inflammatory diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partnerships: Forms strategic collaborations and partnerships to advance their pipeline and expand market reach.
Leadership and Structure
The company has a management team with experience in drug development and immunology. The organizational structure includes departments focused on research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Tibetanide: A novel monoclonal antibody targeting IL-7Ru03b1. It is in clinical development for autoimmune diseases. Market share data is not currently available as it is still in development. Competitors include companies developing therapies for similar autoimmune indications, such as AbbVie, Bristol Myers Squibb, and Johnson & Johnson.
- ZB-106: A fully human anti-CD19 mAb that promotes B-cell depletion and is in preclinical development. No current market share data is available. Competitors are similar to above.
Market Dynamics
Industry Overview
The immunology market is experiencing growth due to the increasing prevalence of autoimmune and inflammatory diseases. There's high demand for novel therapies with improved efficacy and safety profiles.
Positioning
Zura Bio is positioning itself as a key player in the immunology space by developing novel therapeutics with differentiated mechanisms of action. Their competitive advantage lies in its targeted approach.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapeutics is estimated to be hundreds of billions of dollars annually. Zura Bio is attempting to capture a segment of this market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (IL-7Ru03b1, CD19)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Reliance on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new autoimmune and inflammatory indications
- Potential for breakthrough therapies
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- BMY
- JNJ
- LLY
- MRK
Competitive Landscape
Zura Bio is competing with established pharmaceutical companies in the immunology space. Their advantage lies in novel therapeutics, but they lack the scale and resources of larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of their drug candidates through preclinical and clinical stages.
Future Projections: Future growth depends on clinical trial successes and potential FDA approvals. Analyst estimates are contingent on these factors.
Recent Initiatives: Recent initiatives include initiating and advancing clinical trials for Tibetanide.
Summary
Zura Bio is a clinical-stage immunology company with promising therapeutic candidates targeting unmet needs in autoimmune diseases. Their strength lies in their innovative approach, but their success depends on the outcome of ongoing clinical trials. They face significant competition from established players, and careful management of resources is crucial. Partnering with larger companies might de-risk their future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zura Bio Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters Henderson, NV, United States | ||
IPO Launch date 2021-09-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://zurabio.com |
Full time employees 30 | Website https://zurabio.com | ||
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.